Medical Countermeasures
Highly Diluted Dose of Ebola Vaccine Shown Effective in Primate Study
A single dose of VSV-Ebola virus vaccine—approximately one-millionth of what is in the vaccine being used in the outbreak outbreak in the Democratic Republic of the Congo (DRC)—remains fully protective against disease in experimentally infected monkeys, according to...
USAMRIID Study Leads to Approval of New Smallpox Vaccine
A new vaccine approved in the U.S. on Sept. 24 prevents both smallpox and the related disease monkeypox in adults. Marketed under the brand name JYNNEOS, the vaccine was developed by biotechnology firm Bavarian Nordic and tested by...
Bavarian Nordic Announces Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine
Bavarian Nordic A/S announced on 8 Oct. the initiation of the first-in-human trial of MVA-BN® WEV, a prophylactic vaccine candidate against against three separate strains of the equine encephalitis virus, Eastern (EEEV), Venezuelan (VEEV), and Western (WEEV), for...
Radiation Poisoning Countermeasure May Also Protect Against MRI Contrast Agent Toxicity
Rebecca Abergel of Berkeley Lab's Chemical Sciences Division is studying how an anti-radiation-poisoning pill she developed in 2014 could help to protect people from the potential toxicity in the long-term retention of gadolinium, an ingredient in MRI contrast...
BioFactura’s Smallpox Biodefense Therapeutic Awarded $67M BARDA Contract
BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for...
FDA Approves Jynneos to Prevent Smallpox and Monkeypox
The U.S. Food and Drug Administration announced today the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at...
Center for Vaccine Development Awarded up to $201M to Establish Influenza Clinical Core
The Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total...
20 Years of the Strategic National Stockpile: Response History Timeline
The the nation’s largest reserve of medicines and supplies for use in a public health emergency – the Strategic National Stockpile – has supported more than 60 public health responses since its creation in 1999. Originally known as...
Project BioShield: Building a Better Medical Countermeasure Pipeline
Project BioShield has revolutionized the way the United States addresses health security threats, developing essential public-private partnerships for medical countermeasure development. The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (PAHPAIA), signed into law on 24...
Silverlon Wound Dressings Cleared by FDA for Injuries Caused by Mustard Gas
The U.S. Food and Drug Administration (FDA) clearance Silverlon, a product to manage certain blister injuries caused by sulfur mustard, marks the first medical countermeasure for this chemical threat. Silverlon is a silver-plated nylon dressing available commercially and...
BARDA Exercises First Option in Transition from BioThrax to AV7909 Anthrax Vaccine
The Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option with Emergent BioSolutions to procure doses of AV7909 (anthrax vaccine adsorbed with adjuvant) for delivery into the Strategic National Stockpile (SNS) over 12 months....
Study Shows Virulence of B. pseudomallei Strain in Aerosol Model
Burkholderia pseudomallei, the aetiological agent of melioidosis, causes a serious and often fatal disease in humans and animals. Novel medical countermeasures (MCMs) are urgently needed for both public health and biodefense purposes. A new study published this month...
Modeling the Complexities of the Gut for Biodefense Applications
The Nutritional Immunology and Molecular Medicine Laboratory (NIMML), with research funding assistance from the Defense Threat Reduction Agency (DTRA), has developed a high-resolution model of the gut immune system to help solve emerging and re-emerging infectious diseases and...
In Fight Against Superbugs, BARDA Looks to Shore Up National Stockpile Countermeasures
A crisis has arisen from the simultaneous decrease in the number of pharmaceutical companies developing antibiotics and the dramatic increase in the prevalence of infections and deaths caused by antibiotic resistant pathogens. Due to the genetic promiscuity of...
USAID Seeks Innovations in Malaria Vaccine Development
Despite successes in malaria control over the past several decades, over 436,000 people still die from malaria annually and the 2018 World Malaria Report estimates 219 million cases of malaria in 2017. Malaria control programs face several challenges...
Upcoming Events
-
CBD S&T Conference 2019 – Chemical and Biological Defense
November 18 - November 21
